Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.65 2.12 −9.31%
Market cap
$463.6M
P/E
22.3×
Fwd P/E
−21.1×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(0.03%) (5.66%) (5.10%) (36.94%)

+8 more TTM periods

Piotroski F-Score
4 4 — —
ROA
(0.02%) (3.82%) (3.25%) (22.66%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(0.01%) (3.23%) (2.97%) (20.99%)
Average Days of Receivables
4.01 2.32 4.92 8.95
Free Cash Flow per Share
(2.05) (2.36) (3.67) (4.40)
Free Cash Flow
(38.57) (39.84) (41.16) (55.79)
Other line items

Show all line items

Columns are period end dates